IFLScience on MSN

Scheduling cancer immunotherapy in the morning may lower your risk of death by as much as 63 percent

Even if you are a natural late riser, if you’re ever faced with cancer, it might be time to make an exception. A study of ...
CURE

Sac-TMT Combo Shows Benefit in Advanced Lung Cancer Treatment

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...